Tocilizumab (TCZ)
Tocilizumab (TCZ) is a pharmaceutical drug with 6 clinical trials. Historical success rate of 60.0%.
Success Metrics
Based on 3 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
3
Mid Stage
3
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
60.0%
3 of 5 finished
40.0%
2 ended early
0
trials recruiting
6
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Tocilizumab (TCZ) in New-onset Type 1 Diabetes
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia
Tocilizumab for the Treatment of Refractory Behcet's Uveitis
Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
Clinical Trials (6)
Tocilizumab (TCZ) in New-onset Type 1 Diabetes
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia
Tocilizumab for the Treatment of Refractory Behcet's Uveitis
Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
Ultrasound as Imaging Biomarker of Early Response to Tocilizumab and Methotrexate in Very Early Rheumatoid Arthritis
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6